Partners Max Hua (Hong Kong-Capital Markets) and Won Lee (Hong Kong-Capital Markets) moderated and spoke at a panel session on “Focusing in on Hong Kong SAR's biotech listings” at the IFLR Asia Capital Markets Forum 2019 in Hong Kong on November 14. The panel discussed the following:

• Have the new listing rules attracted biotech companies to list on the HKEX
• Comparison of listing requirements for pre-revenue biotech companies in Hong Kong and the U.S.
• Key trends in the biotech IPO landscape

View IFLR Asia Capital Markets Forum 2019.